All In Biotech

Drug Trial Radar · NCT06052748

A Study to Evaluate the Efficacy and Safety of AD-223

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Feb 15, 2024

Primary completion

Mar 27, 2025

Study completion Apr 2, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of AD-223

Conditions

  • Hypertension,Essential

Interventions

  • AD-223ADrug

    PO, Once daily(QD), 8weeks

  • AD-223BDrug

    PO, Once daily(QD), 8weeks

  • AD-223CDrug

    PO, Once daily(QD), 8weeks

  • AD-223A PlaceboDrug

    PO, Once daily(QD), 8weeks

  • AD-223B PlaceboDrug

    PO, Once daily(QD), 8weeks

  • AD-223C PlaceboDrug

    PO, Once daily(QD), 8weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of MSSBPTime frame: Baseline, Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanyang University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.